Replies to post #79 on Affimed NV (AFMD)

[TwoNE1]

AFMD: new Corporate Presentation (May 29, 2019)

https://www.affimed.com/wp-content/uploads/20190529_Affimed_Corporate-Presentation.pdf

AFM13 @15th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (15-ICML)
Lugano, Switzerland

oral presentation (June 22, 2019): 12-month data for AFM13 + Keytruda® (pembrolizumab)
+ poster: Interim data for monotherapy in TCL

see also: http://www.lymphcon.ch/icml/website/doc/15-ICML_ScientificProgram_website.pdf (page 21)


H2 2019 (not H1 2019): Initiate registration-directed study (monotherapy in TCL)